IVIG + Albumin
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postural Tachycardia Syndrome
Conditions
Postural Tachycardia Syndrome
Trial Timeline
Oct 29, 2018 → Dec 1, 2023
NCT ID
NCT03919773About IVIG + Albumin
IVIG + Albumin is a phase 1/2 stage product being developed by Grifols for Postural Tachycardia Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03919773. Target conditions include Postural Tachycardia Syndrome.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03919773 | Phase 1/2 | Completed |
Competing Products
6 competing products in Postural Tachycardia Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ivabradine + Placebo | Amgen | Phase 3 | 76 |
| REGN7544 + Placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |
| IgPro20 + Placebo | CSL | Phase 3 | 76 |
| Efgartigimod | Argenx | Phase 2 | 49 |
| Efgartigimod + Placebo | Argenx | Phase 2 | 49 |
| Northera (Droxidopa) + Placebo + Northera (Droxidopa) + Placebo | Lundbeck | Phase 2 | 49 |